Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 945

Sort by

Sort Order Select

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Blood (2021) 137 (23): 3272–3276.

https://doi.org/10.1182/blood.2020008865

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

May Daher, Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes, Mayela Mendt, Lucila Nassif Kerbauy, Pinaki P. Banerjee, Mayra Shanley, Nobuhiko Imahashi, Li Li, Francesca Lorraine Wei Inng Lim, Mohsen Fathi, Ali Rezvan, Vakul Mohanty, Yifei Shen, Hila Shaim, Junjun Lu, Gonca Ozcan, Emily Ensley, Mecit Kaplan, Vandana Nandivada, Mustafa Bdiwi, Sunil Acharya, Yuanxin Xi, Xinhai Wan, Duncan Mak, Enli Liu, Xin Ru Jiang, Sonny Ang, Luis Muniz-Feliciano, Ye Li, Jing Wang, Shahram Kordasti, Nedyalko Petrov, Navin Varadarajan, David Marin, Lorenzo Brunetti, Richard J. Skinner, Shangrong Lyu, Leiser Silva, Rolf Turk, Mollie S. Schubert, Garrett R. Rettig, Matthew S. McNeill, Gavin Kurgan, Mark A. Behlke, Heng Li, Natalie W. Fowlkes, Ken Chen, Marina Konopleva, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani

Blood (2021) 137 (5): 624–636.

https://doi.org/10.1182/blood.2020007748

Published: 2021

Includes: Supplemental data

Journal Articles

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Dana Stenger, Tanja A. Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G. P. Grünewald, Sebastian Kobold, Dirk H. Busch, Irmela Jeremias, Franziska Blaeschke, Tobias Feuchtinger

Blood (2020) 136 (12): 1407–1418.

https://doi.org/10.1182/blood.2020005185

Published: 2020

Includes: Supplemental data

Journal Articles

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

Livingstone Fultang, Sarah Booth, Orli Yogev, Barbara Martins da Costa, Vanessa Tubb, Silvia Panetti, Victoria Stavrou, Ugo Scarpa, Andris Jankevics, Gavin Lloyd, Andrew Southam, Steven P. Lee, Warwick B. Dunn, Louis Chesler, Francis Mussai, Carmela De Santo

Blood (2020) 136 (10): 1155–1160.

https://doi.org/10.1182/blood.2019004500

Published: 2020

Includes: Supplemental data

Journal Articles

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Joshua A. Hill, Susan K. Seo

Blood (2020) 136 (8): 925–935.

https://doi.org/10.1182/blood.2019004000

Published: 2020

Includes: Supplemental data

Journal Articles

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Wenqun Zhang, Jing Yang, Chunju Zhou, Bo Hu, Ling Jin, Biping Deng, Yang Liu, Shan Wang, Alex H. Chang, Juan Du, Zifen Gao, Yonghong Zhang

Blood (2020) 135 (26): 2425–2427.

https://doi.org/10.1182/blood.2019002008

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

Journal Articles

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong

Blood (2020) 135 (5): 387–391.

https://doi.org/10.1182/blood.2019003293

Published: 2020

Includes: Supplemental data

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Surbhi Sidana, MD, Gita Thanarajasingam, MD, Joan Griffin, PhD, Carrie A. Thompson, MD, Michelle Burtis, Rahma Warsame, MD, Jonas Paludo, MD, Andrea Cheville, Morie A Gertz, MD, Angela Dispenzieri, MD, Jose Villasboas, MD, Stephen M Ansell, MD PhD, S. Vincent Rajkumar, MD, Kathleen J Yost, PhD, N. Nora Bennani, MD, Mustaqeem Siddiqui, MD, Yi Lin, MD PhD, Shaji K. Kumar, MD, Amylou C. Dueck, PhD

Blood (2019) 134 (Supplement_1): 794.

https://doi.org/10.1182/blood-2019-121715

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

NARROW

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only